Payment overview · 2025
General Payments
$109.23
5 reported records · 5 companies
Healthcare provider profile · identity verified
Steven E. Newbold, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SPRINGFIELD, MO · NPI 1447347729
Verified facts
What the public records show
CMS Open Payments records show Steven E. Newbold, M.D. received $109.23 in general payments during 2025 across 5 reported records.
Inspire Medical Systems, Inc. accounted for 27.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $30.14 | 27.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.96 | 21.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.61 | 19.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.36 | 17.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.16 | 13.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $109.23 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $30.14 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $23.96 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.61 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.36 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
26 | 24 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 616 | 93 |
| Atorvastatin Calcium | Atorvastatin Calcium | 449 | 123 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 387 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 368 | 84 |
| Omeprazole | Omeprazole | 275 | 71 |
| Amlodipine Besylate | Amlodipine Besylate | 263 | 67 |
| Losartan Potassium | Losartan Potassium | 229 | 65 |
| Lisinopril | Lisinopril | 216 | 61 |
| Zolpidem Tartrate | Zolpidem Tartrate | 209 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 204 | 46 |
| Tramadol Hcl | Tramadol Hcl | 204 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 194 | 46 |
| Metformin Hcl | Metformin Hcl | 191 | 54 |
| Alprazolam | Alprazolam | 180 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 173 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 163 | 40 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 159 | 22 |
| Oxycodone Hcl | Oxycodone Hcl | 147 | 15 |
| Alendronate Sodium | Alendronate Sodium | 143 | 36 |
| Gabapentin | Gabapentin | 143 | 39 |
| Lorazepam | Lorazepam | 138 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 135 | 35 |
| Clonazepam | Clonazepam | 133 | 20 |
| Potassium Chloride | Potassium Chloride | 128 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 125 | 44 |
| Tizanidine Hcl | Tizanidine Hcl | 121 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 119 | 43 |
| Eliquis | Apixaban | 118 | 21 |
| Jardiance | Empagliflozin | 116 | 25 |
| Carvedilol | Carvedilol | 111 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 102 | 24 |
| Simvastatin | Simvastatin | 101 | 24 |
| Metformin Hcl Er | Metformin Hcl | 100 | 25 |
| Montelukast Sodium | Montelukast Sodium | 100 | 21 |
| Pregabalin | Pregabalin | 98 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 95 | 18 |
| Famotidine | Famotidine | 91 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 89 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 83 | 16 |
| Glimepiride | Glimepiride | 83 | 25 |
| Spironolactone | Spironolactone | 83 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 81 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 78 | 22 |
| Meloxicam | Meloxicam | 71 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 71 | 18 |
| Allopurinol | Allopurinol | 70 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 68 | 19 |
| Sertraline Hcl | Sertraline Hcl | 67 | 21 |
| Trazodone Hcl | Trazodone Hcl | 67 | 16 |
| Furosemide | Furosemide | 66 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 64 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 63 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 63 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 62 | 12 |
| Mounjaro | Tirzepatide | 58 | 15 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 57 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 54 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 52 | 23 |
| Telmisartan | Telmisartan | 51 | 15 |
| Ezetimibe | Ezetimibe | 47 | 12 |
| Mirtazapine | Mirtazapine | 47 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | suppressed |
| Diazepam | Diazepam | 45 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 43 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 37 | 14 |
| Topiramate | Topiramate | 37 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 14 |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Naproxen | Naproxen | 32 | suppressed |
| Prednisone | Prednisone | 31 | 23 |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Ozempic | Semaglutide | 30 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 26 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 26 | 24 |
| Baclofen | Baclofen | 25 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 21 | 19 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 21 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 18 |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Savella | Milnacipran Hcl | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 14 |
| Irbesartan | Irbesartan | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Famciclovir | Famciclovir | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 11 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $109.23 · 5 records | Inspire Medical Systems, Inc. | AREXVY, Cologuard Collection Kit, Dexcom G6 Transmitter, INSPIRE, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error